BLUE Stock Recent News
BLUE LATEST HEADLINES
NEW YORK, NY / ACCESSWIRE / May 16, 2024 / If you suffered a loss on your bluebird bio, Inc. (NASDAQ:BLUE) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/bluebird-bio-lawsuit-submission-form?prid=80314&wire=1 or contact Joseph E. Levi, Esq.
LOS ANGELES , May 16, 2024 /PRNewswire/ -- Glancy Prongay & Murray LLP ("GPM") announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against bluebird bio, Inc. ("bluebird" or the "Company") (NASDAQ: BLUE). Class Period: April 24, 2023 – December 8, 2023 Lead Plaintiff Deadline: May 28, 2024 If you wish to serve as lead plaintiff of the bluebird lawsuit, you can submit your contact information at www.glancylaw.com/cases/bluebird-bio-Inc-1/.
NEW YORK, NY / ACCESSWIRE / May 16, 2024 / If you suffered a loss on your bluebird bio, Inc. (NASDAQ:BLUE) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/bluebird-bio-lawsuit-submission-form?prid=80238&wire=1 or contact Joseph E. Levi, Esq.
NEW YORK, NY / ACCESSWIRE / May 16, 2024 / If you suffered a loss on your bluebird bio, Inc. (NASDAQ:BLUE) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/bluebird-bio-lawsuit-submission-form?prid=80226&wire=1 or contact Joseph E. Levi, Esq.
LOS ANGELES, CA / ACCESSWIRE / May 16, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against bluebird bio, Inc. ("bluebird" or "the Company") (NASDAQ:BLUE) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between April 24, 2023 and December 8, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before May 28, 2024.
Bluebird Bio has launched three gene-editing therapies. These treatments are expensive and complex to administer, and they face stiff competition.
NEW YORK, NY / ACCESSWIRE / May 15, 2024 / If you suffered a loss on your bluebird bio, Inc. (NASDAQ:BLUE) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/bluebird-bio-lawsuit-submission-form?prid=80045&wire=1 or contact Joseph E. Levi, Esq.
bluebird bio, Inc. (NASDAQ:BLUE ) Q1 2024 Results Conference Call May 9, 2024 8:00 AM ET Company Participants Courtney O'Leary - IR Andrew Obenshain - CEO Tom Klima - Chief Commercial and Operating Officer Chris Krawtschuk - CFO Conference Call Participants Jason Gerberry - Bank of America Jack Allen - Baird Gena Wang - Barclays Eric Joseph - JPMorgan Eric Schmidt - Cantor Fitzgerald Lisa Walter - RBC Capital Markets Brooke Schuster - William Blair Operator Thank you for standing by, and welcome to the bluebird bio First Quarter 2024 Results Call. [Operator Instructions] Finally, you are reminded that this conference is being recorded.
bluebird (BLUE) beats sales estimates in the first quarter on increased Zynteglo product revenues. The company is on track with the ongoing launch of its gene therapies.
bluebird (BLUE) plunges 25% year to date as it struggles to fuel the growth of its complex and expensive gene therapies.